Canada OKs Response's heart attack RAMP test:
This article was originally published in Clinica
Response Biomedical has received clearance in Canada to market its RAMP myoglobin assay system for the early diagnosis of heart attacks. The product - which combines the cardiac marker with the firm's RAMP Reader, is an easy-to-use system that can deliver results on-site in less than 15 minutes, says the Vancouver, British Columbia firm. The RAMP Reader was cleared in the US earlier this year for general clinical use, including the myoglobin test. Response hopes to file for regulatory clearance in Canada and the US for two additional cardiac markers - troponin I and CK-MB - before 2003.
You may also be interested in...
As distribution of Regeneron’s monoclonal antibody treatment for coronavirus begins, OWS officials worry about provider confusion with Lilly’s product due to differences in preparation and administration.
The maker of prestige-inspired cosmetics at value prices follows its TikTok viral success by teaming with Kathleen Belsten, aka Loserfruit, the second most-followed female gamer on the Amazon-owned livestreaming platform Twitch.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.